"
GPCR/G ProteinImmunology/Inflammation-
Bilastine?????????H1??????????????????????????????????????????????????????????????????
Histamine Receptor
相关产品
Pitolisant hydrochloride-Perphenazine-Osthole-Clemastine fumarate-Clemizole hydrochloride-Promethazine hydrochloride-Azelastine hydrochloride-Bepotastine Beslilate-Diphenylpyraline hydrochloride-Famotidine-Histamine-Alcaftadine-Cetirizine dihydrochloride-Desloratadine-Ebrotidine-
生物活性
Description
Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria. Target: Histamine H1 ReceptorBilastine binds to histamine H1-receptors as indicated by its displacement of [3H]-pyrilamine from H1-receptors expressed in guinea-pig cerebellum and human embryonic kidney (HEK) cell lines. The studies conducted on guinea-pig smooth muscle demonstrated the capability of bilastine to antagonise H1-receptors. Bilastine is selective for histamine H1-receptors as shown in receptor-binding screening conducted to determine the binding capacity of bilastine to 30 different receptors [1]. Bilastine distribution has an apparent volume of distribution of 1.29 L/kg, and has an elimination half-life of 14.5 h and plasma protein binding of 84-90% [2].
Clinical Trial
NCT01271075
Charite University, Berlin, Germany-Faes Farma, S.A.
Cold Contact Urticaria
September 2010
Phase 2-Phase 3
NCT01081574
Faes Farma, S.A.
Allergic Rhinoconjunctivitis-Chronic Urticaria
January 2010
Phase 1-Phase 2
NCT01124123
Faes Farma, S.A.
Healthy
May 2010
Phase 1
NCT02576041
Menarini International Operations Luxembourg SA
Allergic Rhinitis-Urticaria
October 2015
Phase 4
NCT00572611
Faes Farma, S.A.-Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical Services Ltd-MDS Pharma Services Switzerland AG
Healthy
November 2007
Phase 1
NCT02513290
Universidade do Sul de Santa Catarina
Allergic Rhinitis
August 2013
Phase 4
NCT02213367
Charite University, Berlin, Germany
Chronic Urticaria
July 2014
Phase 3
NCT02761252
Menarini International Operations Luxembourg SA
Seasonal Allergic Rhinoconjunctivitis-Asthma
April 2016
Phase 4
NCT00574379
Faes Farma, S.A.-Merck Sharp & Dohme Corp.-Allied Research International
Seasonal Allergic Rhinitis-Hay Fever-Allergic Conjunctivitis-Hypersensitivity
December 2007
Phase 2
NCT00574210
Faes Farma, S.A.-Allied Research International
Seasonal Allergic Rhinitis-Hay Fever-Rhinoconjunctivitis
October 2007
Phase 2
NCT01400828
Yuhan Corporation
Seasonal Allergic Rhinitis
June 2011
Phase 3
NCT01108783
Faes Farma, S.A.
Seasonal Allergic Rhinitis
April 2003
Phase 3
NCT00420082
Faes Farma, S.A.
Seasonal Allergic Rhinitis
October 2006
Phase 2
NCT00419783
Faes Farma, S.A.
Healthy
August 2006
Phase 1
NCT01127620
Faes Farma, S.A.
Perennial Allergic Rhinitis
May 2004
Phase 3
NCT00504933
Faes Farma, S.A.
Seasonal Allergic Rhinitis
May 2005
Phase 3
NCT00421109
Faes Farma, S.A.
Urticaria
July 2006
Phase 3
NCT01940393
Grupo de Alergología Clínica y Experimental
Urticaria
August 2013
Phase 4
NCT02557269
Association Asthma, Bulgaria-Nasaleze
Seasonal Allergic Rhinitis
May 2015
Phase 4
NCT01271075
Charite University, Berlin, Germany-Faes Farma, S.A.
Cold Contact Urticaria
September 2010
Phase 2-Phase 3
NCT01081574
Faes Farma, S.A.
Allergic Rhinoconjunctivitis-Chronic Urticaria
January 2010
Phase 1-Phase 2
NCT01124123
Faes Farma, S.A.
Healthy
May 2010
Phase 1
NCT02576041
Menarini International Operations Luxembourg SA
Allergic Rhinitis-Urticaria
October 2015
Phase 4
NCT00572611
Faes Farma, S.A.-Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical Services Ltd-MDS Pharma Services Switzerland AG
Healthy
November 2007
Phase 1
NCT02513290
Universidade do Sul de Santa Catarina
Allergic Rhinitis
August 2013
Phase 4
NCT02213367
Charite University, Berlin, Germany
Chronic Urticaria
July 2014
Phase 3
NCT02761252
Menarini International Operations Luxembourg SA
Seasonal Allergic Rhinoconjunctivitis-Asthma
April 2016
Phase 4
NCT00574379
Faes Farma, S.A.-Merck Sharp & Dohme Corp.-Allied Research International
Seasonal Allergic Rhinitis-Hay Fever-Allergic Conjunctivitis-Hypersensitivity
December 2007
Phase 2
NCT00574210
Faes Farma, S.A.-Allied Research International
Seasonal Allergic Rhinitis-Hay Fever-Rhinoconjunctivitis
October 2007
Phase 2
NCT01400828
Yuhan Corporation
Seasonal Allergic Rhinitis
June 2011
Phase 3
NCT01108783
Faes Farma, S.A.
Seasonal Allergic Rhinitis
April 2003
Phase 3
NCT00420082
Faes Farma, S.A.
Seasonal Allergic Rhinitis
October 2006
Phase 2
NCT00419783
Faes Farma, S.A.
Healthy
August 2006
Phase 1
NCT01127620
Faes Farma, S.A.
Perennial Allergic Rhinitis
May 2004
Phase 3
NCT00504933
Faes Farma, S.A.
Seasonal Allergic Rhinitis
May 2005
Phase 3
NCT00421109
Faes Farma, S.A.
Urticaria
July 2006
Phase 3
NCT01940393
Grupo de Alergología Clínica y Experimental
Urticaria
August 2013
Phase 4
NCT02557269
Association Asthma, Bulgaria-Nasaleze
Seasonal Allergic Rhinitis
May 2015
Phase 4
View MoreCollapse
References
[1].Corcostegui, R., et al., Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D, 2005. 6(6): p. 371-84.
[2].Jauregizar, N., et al., Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet, 2009. 48(8): p. 543-54.